OTC:BSEM
READ THE FULL BSEM RESEARCH REPORT
BioStem Technologies, Inc. (OTC:BSEM) is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company states its mission is “to discover, develop and produce the most effective regenerative medicine products in the world,” and we believe that the company is well on its way to achieving that goal—providing to investors what we believe is an opportunity to invest in a company that is both providing a vital service to the human population and providing economic value to shareholders when doing so.
The company has made remarkable progress in growing revenues but one of the many things we appreciate about BioStem is that the company doesn’t rest on its laurels. The company announced that it was initiating a clinical trial to study BioREtain in diabetic foot ulcers. Diabetic foot ulcers are a serious and chronic condition affecting millions of individuals within the diabetic population. According to the American Podiatric Medical Association (APMA), a leading authority on foot and ankle health, approximately 15% of people with diabetes will develop foot ulcers and 6% of these individuals may require hospitalization due to infections or other complications related to their ulcers. The risks for diabetic patients are substantial, with diabetic foot ulcers the leading cause of lower extremity amputations in the U.S. Studies cited by the company indicate that between 14% and 24% of individuals with diabetes who develop foot ulcers will ultimately need an amputation.
We’ve written about the successes of the BioREtain technology before and believe that this will ultimately lead to another important market that the company can expand into. The study will involve 60 patients with non-healing diabetic foot ulcers and has an expected completion date by the end of 2025.
Additionally, the company announced that it has filed with the SEC to register its shares pursuant to the Securities Exchange Act of 1934, which is an important step in its plan to uplist to the Nasdaq stock exchange. We are excited about this likely uplisting and pleased to see this important step in the process. BSEM on the Nasdaq would open up the stock to new investors, especially on the institutional front, that are limited to buying shares listed on major exchanges, providing another potential boost to shares.
These announcements further out belief that BioStem is a company worth paying attention to and that BSEM has solid upside potential. Additionally, we continue to be impressed with the leadership of BioStem, headed by CEO Jason Matuszewski, which has remained confident in its products and science, while also focusing on getting the improved solution out to patients and accelerating commercial growth—as is demonstrated by continue to test its proven technology on other debilitating conditions.
Summary
We reiterate our belief the BSEM is still underpriced even after its recent move higher and continues to represent a good opportunity at recent prices for investors to get in before what we believe will be a more aggressive move higher in the not-too-distant future. The vision management has for the company’s products and the focus they are using to deliver results are encouraging and are now being rewarded by increased demand. As such, we urge investors to take a good look at BSEM.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
